Runimotamab is under clinical development by Genentech USA and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 69% phase transition success rate ...

In 2025, the government will issue additional standards to be published in categories such as green hydrogen production, storage and transportation, its various applications such as in aviation ...

The holiday travel season has officially begun at Tampa International Airport. From Dec. 19 through Jan. 6, TPA expects to see an estimated 1.5 million people pass through the terminals. Dec. 26 is ...

(RTTNews) - Genentech, a member of the Roche Group (RHHBY), announced that its phase IIb study of Prasinezumab in early-stage Parkinson's disease missed the primary endpoint, but data suggested ...

The effectiveness of alteplase and urokinase in restoring adequate hemodialysis blood-flow rates was examined. A retrospective review of the medical records of hemodialysis patients with central ...

The thrombolytic protocol was approved by the institutional review board. Alteplase (Activase, Genentech) was prepared in 1-mL portions at a concentration of 1 mg/mL from 50-mg alteplase vials in ...

(RTTNews) - Genentech, a member of the Roche Group (RHHBY), announced that the U.S. Food and Drug Administration has accepted the company's supplemental Biologics License Application (sBLA ...